BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27187604)

  • 1. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
    Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
    Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.
    Lv S; Song Q; Chen G; Cheng E; Chen W; Cole R; Wu Z; Pascal LE; Wang K; Wipf P; Nelson JB; Wei Q; Huang W; Wang Z
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells.
    Dong J; Wu Z; Wang D; Pascal LE; Nelson JB; Wipf P; Wang Z
    Mol Cancer Ther; 2019 Jan; 18(1):39-50. PubMed ID: 30297360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
    Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
    Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
    Masoodi KZ; Eisermann K; Yang Z; Dar JA; Pascal LE; Nguyen M; O'Malley K; Parrinello E; Feturi FG; Kenefake AN; Nelson JB; Johnston PA; Wipf P; Wang Z
    Endocrinology; 2017 Oct; 158(10):3152-3161. PubMed ID: 28977599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (+)-JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist.
    Cole RN; Chen W; Pascal LE; Nelson JB; Wipf P; Wang Z
    Mol Cancer Ther; 2022 Apr; 21(4):483-492. PubMed ID: 35058329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
    Pollock JA; Wardell SE; Parent AA; Stagg DB; Ellison SJ; Alley HM; Chao CA; Lawrence SA; Stice JP; Spasojevic I; Baker JG; Kim SH; McDonnell DP; Katzenellenbogen JA; Norris JD
    Nat Chem Biol; 2016 Oct; 12(10):795-801. PubMed ID: 27501397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
    Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
    Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
    Li H; Xie N; Gleave ME; Dong X
    Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
    Hua Y; Shun TY; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2014 Sep; 12(7):395-418. PubMed ID: 25181412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.